COHANCE Cohance Lifesciences Q3 FY26 results (Oct–Dec 2025) and concall
Management summary
- Cohance Lifesciences reported a challenging Q3 and nine months FY26, with significant revenue and EBITDA declines attributed to destocking, regulatory issues at its Nacharam facility, and biotech funding slowdowns.
- Despite the near-term headwinds, the company is actively rebuilding its pipeline across CDMO, API Plus, and Specialty Chemicals, securing new customer engagements and maintaining its long-term growth and margin targets.
- Management expects FY27 to be a year of growth, driven by pipeline execution and recovery.
Source: Inve concall analysis and management guidance record.
Highlights
-
Gross margins improved to 72.8% for 9M FY26, up 204 basis points YoY.
-
Strong new customer engagement in Pharma CDMO, with increased late-stage RFP activity and deepening relationships with top 10 global pharmaceutical companies.
-
Secured a commercial KSM opportunity with a Western CDMO, with supplies expected from H2 FY27.
-
Filed one new ADC payload, with work ongoing on three additional filings in FY27.
What they filed
Q3 FY26: revenue down 19.5%, net profit down 81.1% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 676 | 840 | 549 | 556 | 545 −19% |
| EBITDA | 237 | 229 | 112 | 121 | 95 −60% |
| Net profit | 153 | 117 | 46 | 66 | 29 −81% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Revenue Growth Revenue · FY26 · Medium confidence early-to-mid double-digit decline
Revenue Growth Revenue · FY27 · Medium confidence growth
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2FY27 Revenue Growth Outlook Partial
No, yes, we are fully working for growth in FY '27.
Confirms management's expectation of recovery in FY27 after a challenging FY26, but lacks quantification.
Asked by Foram Parekh
Quantifying FY27 Blended Growth Evasive
I would request you and the community to be patient with us and give us some more time for us to validate, test and give you more color to FY '27 in one or two quarters.
Indicates uncertainty or unwillingness to commit to specific numbers for FY27 at this stage, despite expecting growth.
Asked by Foram Parekh
Unlock risks & concerns, Q4 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 10 risks, concerns & management red flags
- 5 watchlist triggers for Q4 FY26
- +9 more guidance targets & verbatim management quotes
- +5 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





